Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Endometrial Cancer Clinical Trials
A listing of Endometrial Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Mobile : University of South Alabama / Mitchell Cancer Institute Univ South Alabama
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Arizona
Pheonix : St. Joseph's Hospital and Medical Center
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
California
Concord : John Muir Clinical Research Center
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Fullerton : St. Jude Heritage Medical Group St Jude
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Los Angeles : Cedars Sinai Medical Center TKI258A2211 (SC)
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Los Angeles : UCLA/ University of California Los Angeles UCLA 3
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Los Angeles : USC/Kenneth Norris Comprehensive Cancer Center USC 2
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
View More »
Santa Maria : Central Coast Medical Oncology Corporation
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Colorado
Greenwood Village : Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Connecticut
Farmington : University of Connecticut Health Center
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
New Haven : Smilow Cancer Hospital at Yale New Haven
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
New Haven : Yale University School of Medicine
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
Florida
Orlando : Florida Hospital Cancer Institute FL Hosp
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Georgia
Savannah : Memorial University Medical Center
GOG-0229K: A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Savannah : Memorial University Medical Center
GOG-0229L: A Phase II Trial of AMG 386 (IND# ), a Selective Angiopoietin ½ Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Indiana
Indianapolis : Indiana University Health Goshen Center for Cancer IU Simon Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Maryland
Baltimore : Greater Baltimore Medical Center
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Michigan
Detroit :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Detroit : Investigational Site Number 1326
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer
Nebraska
Lincoln : Southeast Nebraska Oncology Cancer Center
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
New York
Bronx : Montefiore Medical Center
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
New York :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
North Carolina
Asheville : Hope A Woman's Cancer Center
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Chapel Hill : University of North Carolina
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Durham : Duke University Medical Center Duke3
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Durham : Duke University School of Medicine
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Ohio
Hilliard : The Ohio State University
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Rhode Island
Providence : Investigational Site Number 1142
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer
South Carolina
Greenville : Cancer Centers of the Carolinas SC-1
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Tennessee
Chattanooga : Community Oncology Research Network
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Memphis : The West Clinic SC
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Nashville : Vanderbilt University Medical Center SC-2
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Nashville :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Texas
Bedford : Texas Oncology, P.A. Tex Onc (3)
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Bedford : Texas Oncology, P.A. Austin
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Fort Worth : Texas Oncology, P.A. SC
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Houston : UT MD Anderson Cancer Center
Chemoradiation-Induced Nausea and Emesis: Quality of Life
San Antonio : South Texas Oncology and Hematology, PA South Tex Onc
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Virginia
*see Various Departments* : Virginia Oncology Associates VOA - Lake Wright
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Washington
Spokane : Cancer Care Northwest SC
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Belgium
Wilrijk : Investigational Site Number 3218
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer
Brazil
Belo Horizonte : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Porto Alegre : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Ribeirao Preto : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Italy
Candiolo : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Milano : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Pisa : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Korea, Republic of
Seoul : Asan Medical Center
Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer
Seoul : Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer
New Zealand
Grafton, Auckland : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Spain
Barcelona : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Córdoba : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Majadanonda : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Málaga : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Sabadell : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
United Kingdom
Nottingham : Novartis Investigative Site
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
